Text Size

Transient receptor potential vanilloid 1 agonists as candidates for anti-inflammatory and immunomodulatory agents

Tsuji F., Murai M., Oki K., Seki I., Ueda K., Inoue H., Nagelkerken L., Sasano M., Aono H.


  • 2010
  • European Journal of Pharmacology
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Technology

    Other

  • Affiliations

    Research and Development Center, Santen Pharmaceutical Co., Ltd., 8916-16 Takayama-cho, Ikoma-shi, Nara, 630-0101, Japan; United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagido, Gifu-shi, Gifu, 501-1193, Japan; Department of Inflammatory and Degenerative Diseases, TNO Quality of Life, Zernikedreef 9, 2333 CK Leiden, Netherlands; Functional Polymer Science Laboratory, Graduate School of Materials Sciences, Nara Institute of Science and Technology, 8916-5 Takayama-cho, Ikoma-shi, Nara, 630-0192, Japan

Related Publications

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis

Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, Amrane M, Ismail D, Doan S, Bremond-Gignac D.


Correlation between gene expression and clinical scores in vernal keratoconjunctivitis

Leonardi A, Cavarzeran F, Rosani U, Righetti G, Garrigue JS, Brun P.


Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials

Leonardi A, Doan S, Aragona P,  Amrane M, Ismail D, Montero J, Németh J, Bremond-Gignac D


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022